Clinical trials: Neoadjuvant Chemoimmunotherapy
Non-small Cell Lung Cancer Stage ⅢA, Non-small Cell Lung Cancer Stage IIIB
Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
to explore the impact of preoperative neoadjuvant immunotherapy on perioperative outcomes and long-term prognosis of locally advanced NSCLC in the real world
- Trial name
- NCT06394427
- Testing
- cycles of neoadjuvant therapy and duration of waiting for surgery
- Volunteers
- 250 people
- Sponsor
- West China Hospital
Immunotherapy, Gastric Cancer (GC)
Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
Neoadjuvant radiotherapy plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)
- Conditions
- Immunotherapy, Gastric Cancer (GC), Radiotherapy, Neoadjuvant Therapy
- Trial name
- NCT07165847
- Testing
- Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Triple Negative Breast Cancer
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who…
- Trial name
- NeoCARD (NCT06845319)
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Triple Negative Breast Cancer
Radiological Prediction of Response to Neoadjuvant Chemoimmunotherapy for Triple-negative Breast Cancer
The aim of our study is to find the best imaging technique, alone or in combination, that can best predict a complete response (absence of tumour cells).
- Trial name
- PRECISION (NCT06879704)
- Testing
- Imaging assessment
- Where
- France
- Volunteers
- 115 people
- Sponsor
- Centre Henri Becquerel
Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant Chemoimmunotherapy
Adebrelimab Combined With Carboplatin and Albumin-bound Taxanol in the Treatment of Resectable Locally Advanced Oral Squamous Cell Carcinoma Cardiac, Randomized, Phase II Exploratory Study
Neoadjuvant immunochemotherapy can effectively increase the postoperative pathological complete response rate, improve the survival rate of patients, and reduce the risk of recurrence in oral squamous cell carcinoma (OSCC).
- Trial name
- NCT07137858
- Testing
- Preoperative neoadjuvant immunotherapy chemotherapy, Two courses of preoperative neoadjuvant immunotherapy chemotherapy, Three courses of preoperative neoadjuvant immunotherapy chemotherapy
- Volunteers
- 70 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on…
- Trial name
- NeoTILs (NCT07743190)
- Testing
- Carboplatin, Paclitaxcel, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical University of South Carolina
Oral Squamous Cell Carcinoma (OSCC), Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Rimegepant-Sensitized Neoadjuvant Chemoimmunotherapy for Oral or Oropharyngeal Squamous Cell Carcinoma
This study will evaluate whether adding rimegepant to standard neoadjuvant chemoimmunotherapy can improve treatment response in patients with primary or recurrent oral or oropharyngeal squamous cell carcinoma who are planned to…
- Trial name
- NCT07812467
- Testing
- Rimegepant, Tislelizumab, Nab-paclitaxel
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Glioblastoma
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
The primary purpose of this study is to test the safety of Pembrolizumab and Temozolomide in treating recurrent glioblastoma and to characterize the effect of this treatment on the participants tumor and immune system..
- Trial name
- NCT05700955
- Testing
- Pembrolizumab and Temozolomide
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Louisville
Esophageal Squamous Cell Carcinoma
Tumor Microenvironment Changes After Neoadjuvant Chemo-Immunotherapy in Esophageal Squamous Cell Carcinoma
This prospective observational study aims to characterize dynamic changes in the tumor microenvironment of patients with esophageal squamous cell carcinoma receiving standard neoadjuvant chemotherapy combined with immunotherapy…
- Trial name
- TME-ESCC (NCT07482774)
- Testing
- Biological: Tumor Tissue and Blood Sample Collection
- Volunteers
- 12 people
- Sponsor
- Nanjing Medical University
Breast Cancer, Triple Negative Breast Cancer
Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial
Italian, multicenter, open-label, two-arm, comparative, randomized phase II study investigating if the addition of the experimental metabolic intervention consisting in cycles of Fasting-Like Approach, as administered every three…
- Conditions
- Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting
- Trial name
- BREAKFAST-2 (NCT05763992)
- Testing
- Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
- Where
- Italy
- Volunteers
- 145 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lung Cancer
Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer
Predicting relapse and overall survival in potentially resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) patients remains challenging.
- Trial name
- NCT06267144
- Testing
- Sintilimab plus chemotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy
Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.
This is an open-label, randomized, controlled, multicenter phase III clinical trial designed to evaluate the efficacy and safety of spatially fractionated stereotactic body radiotherapy (SF-SBRT) combined with toripalimab and…
- Conditions
- Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy, Neoadjuvant Chemoimmunotherapy, Surgery
- Trial name
- NCT07608159
- Testing
- Stereotactic body radiotherapy (SBRT), neoadjuvant immunotherapy, Neoadjuvant Chemotherapy
- Volunteers
- 201 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Esophageal Cancer
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy.
- Trial name
- SORT (NCT07162506)
- Testing
- Surgery, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non Small Cell Lung Cancer
A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC
To evaluate the efficacy and safety adebrelimab in Combination with chemotherapy after 3 cycles as neoadjuvant therapy and surgery or chemoradiotherapy based on MDT compared with adebrelimab after chemoradiotherapy in potentially…
- Trial name
- NCT06424899
- Testing
- Adebrelimab, radical chemoradiotherapy, Platinum based chemotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zeng Jian
Esophageal Squamous Cell Carcinoma
Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma
The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy…
- Trial name
- NCT07488624
- Where
- 3 sites in China
- Volunteers
- 414 people
- Sponsor
- Sichuan University
Triple-negative Breast Cancer (TNBC), Stage II-III
Emergence of Predictive Metabolomic Biomarkers of Response to Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer.
The goal of this study is to investigate whether specific metabolic profiles can predict response to neoadjuvant chemo-immunotherapy in patients with stage II and III triple-negative breast cancer (TNBC).
- Trial name
- EMMENEO-TN (NCT07847398)
- Testing
- Blood sampling, Tumor sampling
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Antoine Lacassagne
Recurrent Head and Neck Squamous Cell Carcinoma
Anti-PD-1 Therapy in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma
The goal of this clinical trial is to determine whether a perioperative PD-1 antibody-based treatment strategy, consisting of neoadjuvant PD-1 antibody plus chemotherapy followed by adjuvant PD-1 antibody after surgery, improves…
- Trial name
- neo-Recur (NCT07751289)
- Testing
- Neoadjuvant PD-1 antibody plus chemotherapy, surgery, Adjuvant PD-1 antibody
- Volunteers
- 217 people
- Sponsor
- Yanjie Zhang, MD
Esophageal Squamous Cell Carcinoma
Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CRIS-2 Trial）
Based on our previous single-arm Phase Ib study (CRIS trial, NCT06303583), we observed that neoadjuvant chemoradiotherapy followed by immunotherapy (nCRIT) significantly increased the pathological complete response (pCR) rate…
- Trial name
- NCT06509568
- Testing
- Neoadjuvant chemoradiotherapy followed by immunotherapy, Neoadjuvant chemoimmunotherapy
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Zhejiang Cancer Hospital
Locally Advanced Oral Squamous Cell Carcinoma
Prospective Cohort Study on Oral Microbiome Changes in Patients With Locally Advanced Oral Squamous Cell Carcinoma Following Neoadjuvant Chemoimmunotherapy
Investigating the Relationship Between Oral Microbiome Alterations and Tumor Markers in Locally Advanced Oral Squamous Cell Carcinoma (LA-OSCC) After Neoadjuvant Chemoimmunotherapy: Implications for Therapeutic Efficacy…
- Trial name
- NCT07111455
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Zhujiang Hospital
Non-Small Cell Lung Cancer
A Study Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiation for Borderline Resectable Non-Small Cell Lung Cancer
The purpose of this research study is to find out if adding radiation prior to chemoimmunotherapy and surgery is effective for people with non-small cell lung cancer (NSCLC) who have the potential for surgery.
- Trial name
- NEORADJUVANT (NCT06800339)
- Testing
- Nivolumab, Chemotherapy, SBRT
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Maryland, Baltimore